Literature DB >> 11739845

Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients.

E Gallardo1, R Rojas-García, N de Luna, A Pou, R H Brown, I Illa.   

Abstract

Inflammation was detected in 9 of 13 patients with different phenotypes of dysferlin myopathy. Endomysial or perivascular infiltrates consisted of 11.1% +/- 6.6% CD8(+) cells, 40.6% +/- 22.8% CD4(+) cells, 36.7% +/- 23.7% macrophages, and no B cells. Major histocompatibility complex class I was not upregulated in normal muscle fibers. In young patients with sporadic proximal weakness, very high creatine kinase levels, necrotic fibers and inflammation in the muscle biopsy, a diagnosis of dysferlin myopathy should be considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739845     DOI: 10.1212/wnl.57.11.2136

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  58 in total

1.  Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis.

Authors:  Isabelle Pénisson-Besnier; Jean-Paul Saint-André; Debbie Hicks; Anna Sarkozy; Anne Croué; Judith Hudson; Hanns Lochmüller; Frédéric Dubas
Journal:  J Neurol       Date:  2012-04-19       Impact factor: 4.849

Review 2.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 3.  The utility of muscle biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

4.  Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.

Authors:  Joseph J Belanto; Silvia V Diaz-Perez; Clara E Magyar; Michele M Maxwell; Yasemin Yilmaz; Kasey Topp; Guney Boso; Catriona H Jamieson; Nicholas A Cacalano; Christina A M Jamieson
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

5.  Quantitation of the calcium and membrane binding properties of the C2 domains of dysferlin.

Authors:  Nazish Abdullah; Murugesh Padmanarayana; Naomi J Marty; Colin P Johnson
Journal:  Biophys J       Date:  2014-01-21       Impact factor: 4.033

6.  Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy.

Authors:  Douglas P Millay; Marjorie Maillet; Joseph A Roche; Michelle A Sargent; Elizabeth M McNally; Robert J Bloch; Jeffery D Molkentin
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

7.  Clinical and genetic analysis of Korean patients with Miyoshi myopathy: identification of three novel mutations in the DYSF gene.

Authors:  Hyun-Jung Cho; Duck Hyun Sung; Eun-Jin Kim; Chul Ho Yoon; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

8.  Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.

Authors:  Sree Rayavarapu; Jack H Van der Meulen; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju; Susan M Knoblach
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

9.  Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy.

Authors:  Yen-Hui Chiu; Mark A Hornsey; Lars Klinge; Louise H Jørgensen; Steven H Laval; Richard Charlton; Rita Barresi; Volker Straub; Hanns Lochmüller; Kate Bushby
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  Differential immunohistological features of inflammatory myopathies and dysferlinopathy.

Authors:  Jae-Hwan Choi; Yeong-Eun Park; Sung-Il Kim; Jeong-Il Kim; Chang-Hoon Lee; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.